Watson Pharmaceuticals, Inc, a leading specialty pharmaceutical company, announced that its subsidiary Watson Laboratories, Inc has reached a settlement with Barr Laboratories, Inc on outstanding patent litigation related to Watson's Oxytrol (Oxybutynin Transdermal System, 3.9mg/24hr.) product.
On August 19, 2008, Barr submitted an Abbreviated New Drug Application (ANDA) seeking approval to market a generic version of Oxytrol. Under terms of the settlement agreement, Watson has granted Barr a royalty-bearing license to the US patents covering Oxytrol to commence marketing a generic equivalent product on April 26, 2015, or earlier in certain circumstances.
Watson Pharmaceuticals is a global leader in the development and distribution of pharmaceuticals with a broad portfolio of generic products and a specialized portfolio of branded pharmaceuticals focused on urology, gynaecology and nephrology (Medical).